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Abstract
The 27-mer peptide CP1B-w1–27x derived from exon 1B
of calpastatin stands out among the known inhibitors for
m- and m-calpain due to its high potency and selectivity.
By systematical truncation, a 20-mer peptide, CP1B-
w4–23x, was identified as the core sequence required to
maintain the affinity/selectivity profile of CP1B-w1–27x.
Starting with this peptide, the turn-like region Glu10(i)-
Leu11(iq1)-Gly12(iq2)-Lys13(iq3) was investigated. Se-
quence alignment of subdomains 1B, 2B, 3B and 4B
from different mammalians revealed that the amino acid
residues in position iq1 and iq2 are almost invariably
flanked by oppositely charged residues, pointing towards
a turn-like conformation stabilized by salt bridge/H-bond
interaction. Accordingly, using different combinations of
acidic and basic residues in position i and iq3, a series
of conformationally constrained variants of CP1B-w4–23x
were synthesized by macrolactamization utilizing the side
chain functionalities of these residues. With the combi-
nation of Glu(i)/Dab(iq3), the maximum of conformational
rigidity without substantial loss in affinity/selectivity was
reached. These results clearly demonstrate that the linear
peptide chain corresponding to subdomain 1B reverses
its direction in the region Glu10-Lys13 upon binding to
m-calpain, and thereby adopts a loop-like rather than a
tight turn conformation at this site.
Keywords: cysteine protease; macrolactamization;
peptidomimetic; protease inhibitor.
Introduction
The calpains constitute a family of calcium-dependent
cysteine proteases (clan CA, family C2) (Barrett et al.,
1998). Among them, the ubiquitous mammalian calpains,
m-calpain and m-calpain, are by far the best-character-
ized members of this family. Both enzymes exhibit their
catalytic activity in the cytosol at neutral pH. m-Calpain
reaches its half-maximal activity at calcium concentra-
tions in the micromolar range, whereas m-calpain needs
millimolar calcium concentrations to be active. The ubi-
quitous calpains are heterodimeric proteins composed of
a large subunit of approximately 80 kDa harboring the
catalytic activity and a small 28-kDa subunit proposed
to exhibit regulatory activities. Whereas the small subunit
is identical for both enzymes, the large subunits share
55–65% sequence homology between the two proteases
(for recent reviews see Sorimachi and Suzuki, 2001; Goll
et al., 2003). The X-ray structures of calcium-free rat and
human m-calpain have elucidated the structural organ-
ization of the enzyme (Hosfield et al., 1999; Strobl et al.,
2000). In particular, the large subunit is composed of six
domains. Two of them (domain IIa and IIb) constitute the
catalytic core with an overall papain-like fold.
Besides the local calcium concentration, the endoge-
nous protein-type inhibitor calpastatin plays an important
role in the regulation of calpain activity (for a recent
review see Wendt et al., 2004). Calpastatin is widely dis-
tributed in mammalian tissues. Upon calcium activation,
calpastatin specifically binds to the calpains in a revers-
ible fashion. Calpastatin comprises five domains: an
N-terminal, so-called L-domain without inhibitory activity
and four repetitive inhibitory domains (1–4), each of them
organized in three subdomains (A, B and C). Only sub-
domain B is able to block the catalytic activity of calpain,
whereas peptides representing subdomains A and C
activate calpain in vitro (Tompa et al., 2002) and in the
cell (Ba´no´czi et al., 2007). Subdomains A and C have
been shown to bind to domain IV of the large and domain
VI of the small subunit of calpain, respectively (Takano et
al., 1995), subdomain B is proposed to interact with an
area near the active site (domain IIa and/or IIb).
In the last decade, several attempts have been under-
taken to obtain a detailed picture of the interaction mode
of calpastatin with calpain at the atomic level. Of partic-
ular interest in this context is the bound conformation of
the 27-mer peptide, CP1B-w1–27x (compound 1; see Fig-
ure 1A), derived from subdomain 1B of human calpas-
tatin, because this peptide inhibits calpain almost as
efficiently as the parent whole inhibitory domain 1 of the
protein (Maki et al., 1989). Amongst the synthetic calpain
inhibitors that have been developed so far (for reviews
see Wells and Bihovsky, 1998; Donkor, 2000), CP1B-
w1–27x (1) stands out due to its unequaled affinity/select-
ivity profile. Consequently, these unique properties have
been utilized in cell biological studies. By conjugation
with penetratin, a cell-permeable variant of CP1B-w1–27x
(1) was obtained that is ideally suited as a tool to study
the (patho)physiological roles of the ubiquitous calpains
(Gil-Parrado et al., 2003). For now, investigations of
domain 1 of human (Uemori et al., 1990) and porcine
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Figure 1 Structure of linear (A) and conformationally con-
strained (B) calpastatin peptides.
Peptide 12: ‘---’ represents 8-amino-3,6-dioxaoctanoic acid
replacing the tripeptide portion Arg14-Glu15-Val16 spatially; pep-
tide 13: the lower case letters indicate the corresponding
D-amino acids.
(Konno et al., 1997) calpastatin in aqueous solution both
by 1H-NMR and CD spectroscopy have revealed that
the protein is highly flexible and has no well-defined
3D structure. Thus, calpastatin has been classified as
a member of the group of ‘intrinsically unstructured
proteins’ (Tompa, 2002; Uversky, 2002). Consequently,
further efforts to obtain structural data of an inhibitory
domain of calpastatin addressed the calpain-bound state
of the protein. CD studies with peptides derived from
subdomain A and C point to a a-helical conformation for
both peptides (Mucsi et al., 2003). Subsequently, the
X-ray structure of a 19-mer domain 1C peptide of cal-
pastatin in complex with domain VI of calpain has
revealed a a-helical conformation and confirmed the CD
studies (Todd et al., 2003). Based on this structure, a
homology model of the complex of a 19-mer domain 1A
peptide of calpastatin and domain IV of calpain has been
built and also supports an a-helical conformation (Todd
et al., 2003). However, until now, no X-ray data are avail-
able for calpain-bound subdomain B. NMR studies in
DMSO, which is expected to mimic a structure-inducing
environment, have shown that the residues Glu10-Leu11-
Gly12-Lys13 and Pro20-Lys21-Tyr22-Arg23 of CP1B-w1–27x (1)
adopt a turn-like conformation. However, regular struc-
tural elements, such as an a-helix or a b-sheet, have not
been identified (Ishima et al., 1991). The importance of
the amino acid residues Leu11 and Gly12 for the inhibitory
activity of CP1B-w1–27x (1) has been confirmed by a
combination of a b-alanine/alanine scan (Betts et al.,
2003). Additionally, the residues Thr17, Ile18 and Pro19 have
been identified to strongly contribute to the inhibitory
activity of CP1B-w1–27x (1) (Betts et al., 2003). N-term-
inally and C-terminally truncated variants of CP1B-w1–27x
(1) have revealed that almost the complete sequence is
necessary to maintain the inhibitory potency (Betts and
Anagli, 2004).
From these SAR data obtained so far, describing the
influence of linear modifications within the sequence of
CP1B-w1–27x (1), only little information could be derived
about the 3D architecture in the bound state. To reduce
the conformational space of a linear peptide sequence,
a typical approach is to synthesize cyclic versions of the
interesting sequence portions by macrolactamization. In
particular, those portions supposed to be part of turns
are of greatest interest. However, in the case of a long
peptide as the 27-mer CP1B-w1–27x (1), it is generally
difficult to identify suitable sites within the sequence for
macrolactamization. Our attention was attracted by the
sequence portion Glu10-Leu11-Gly12-Lys13 that has been
proposed to adopt a turn-like conformation (Ishima et al.,
1991). The crucial residues Leu11 and Gly12 (Betts et al.,
2003), occupying the positions iq1 and iq2 of the puta-
tive turn, respectively, are flanked sequentially by an
acidic and a basic amino acid residue that possibly stab-
ilize the turn-like conformation via salt bridge formation
and provide the chemical prerequisite for macrolactam-
ization. In this study, we investigated the influence of
macrolactamization at this site on the inhibitory potency
of CP1B in a systematical manner. To reduce the syn-
thetic effort, a truncated version of CP1B, the 20-mer
CP1B-w4–23x (7), was used. We identified CP1B-w4–23x
(7) as core sequence necessary to essentially maintain
the affinity/selectivity profile of full-length CP1B, taking
into account the selectivity aspect that had been neglect-
ed in the previously published truncation studies (Betts
and Anagli, 2004).
Results
Selectivity profiles of truncated linear calpastatin
peptides
To assess the selectivity profile of truncated calpastatin
peptides within the group of papain-like cysteine prote-
ases, we have selected cathepsin B and L as represent-
ative probes. Three groups of truncated calpastatin pep-
tides were synthesized on solid support by the standard
Fmoc/tBu scheme. The first and the second group com-
prise N-terminally and C-terminally truncated variants of
CP1B-w1–27x (1), respectively, whereas the third group
includes peptides truncated at both termini (Figure 1A).
The measured Ki values of these peptides for the inhi-
bition of m-calpain, cathepsin B and L are summarized
in Table 1. N-terminal truncation by three and five (3 and
4, respectively) as well as C-terminal truncation by two
and four amino acid residues (5 and 6, respect-
ively) does not influence the affinity/selectivity profile sig-
nificantly compared to 1. Among the calpastatin peptides
truncated at both termini, CP1B-w4–23x (7) is the most
potent inhibitor (Kis26 nM), which blocks the proteolytic
activity m-calpain by a factor of 1000 more efficiently
than that of cathepsin L. Moreover, peptide 7 marks a
limit for the truncation tolerated at both termini. Beyond
this limit, as clearly documented by 8 and 9, a total loss
of affinity and selectivity was observed. To reduce the
synthetic effort, we have replaced CP1B-w1–27x (1) by
CP1B-w4–23x (7) in all further SAR-investigations.
SAR studies based on linear calpastatin peptides
To gain information on the individual roles of the two turn-
like structural elements, the inhibitory properties of the
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Table 1 Activity/selectivity profiles of linear and conformationally constrained cal-
pastatin peptides.
Inhibitor m-Calpain Cathepsin L Cathepsin B Ratio, CL/m-calpain
Ki (mM)a Ki (mM)a Ki (mM)a
1 0.0002b 6b G500b 30 000
2 6b 6b G500b 1
3 0.0006 9.5 G600 15 830
4 0.0022 9.7 G600 4410
5 0.0005 45 G600 90 000
6 0.0008 21 G600 26 250
7 0.026 20 n.d. 1000
8 0.093 15 4.3 161
9 17 124 G900 7.3
10 6.9 1.0 60 0.14
11 35 10 G200 0.29
12 11.7 28 n.d. 2.4
13 726 44 32 0.06
14 0.036 15 G400 420
15 0.039 13 G400 330
16 0.027 18 G400 230
17 1.4 1.3 3.7 0.9
aMean of 5–10 experiments with different inhibitor concentrations (SD-10%). Val-
ues marked by ‘G’ are 10-fold the highest used inhibitor concentration that resulted
in less than 10% inhibition.
bData taken from Gil-Parrado et al. (2003).
n.d., not determined.
peptides 10 and 11, representing the first and second
half of CP1B-w1–27x (1), respectively, were analyzed
(Table 1). In particular, peptide 10 comprising the turn-
like sequence Glu10-Leu11-Gly12-Lys13 is only a poor inhib-
itor of m-calpain (Kis6.9 mM). Similarly, peptide 11 that
includes the residues Pro20-Lys21-Tyr22-Arg23 being part of
the second turn-like structural element, inhibitsm-calpain
with even lower affinity (Kis35 mM). Considering the tri-
peptide sequence Arg14-Glu15-Val16 merely as a linker that
connects the two turn-like structural elements, a peptide
was designed where this connecting sequence was
replaced by a non-peptidic spacer. The flexible PEG
amino acid 8-amino-3,6-dioxaoctanoic acid was select-
ed as a spacer, which should provide a spatial substitu-
tion for the tripeptide portion. The kinetic analysis of
this peptide 12 revealed poor inhibitory properties
(Kis11.7 mM). Furthermore, we applied the retro-inverso
approach on the sequence of our truncated calpastatin
peptide CP1B-w4–23x (7). It turned out that the corre-
sponding retro-inverso derivative 13 is almost completely
inactive (Kis726 mM).
Sequence alignment of the turn-like region
Glu10-Leu11-Gly12-Lys13 of CP1B-w4–23x (7)
In a next step, to obtain a more precise picture of the
conformation that the core sequence (7, CP1B-w4y23x)
adopts upon binding to m-calpain, the turn-like region,
i.e., Glu10-Leu11-Gly12-Lys13 was investigated. A syste-
matical amino acid sequence alignment of subdomains
1B, 2B, 3B and 4B of calpastatin revealed that this region
is highly conserved among different species (Figure 2). In
particular, the residues iq1 (Leu/Cys) and iq2 (Gly) of the
turn-like region are flanked by a basic and an acidic res-
idue in a pairwise manner. In the case of subdomain 1B,
position i is occupied by a Glu and position iq3 by a Lys
residue, whereas in the case of subdomains 2B, 3B and
4B the situation is reversed (Lys in position i and Glu in
position iq3). Only subdomain 1B from rat and mouse,
as well as bovine subdomain 3B, differ from this pattern.
Furthermore, the position preceding this turn-like region
(i-1) is occupied by an acidic amino acid residue (Asp/
Glu), the position following this turn-like region (iq4) by
a basic amino acid residue (Arg/Lys). However, amongst
all species included in the alignment, the subdomains 2B
deviate substantially from this pattern.
Design and synthesis of conformationally
constrained versions of CP1B-w4–23x (7)
The consensus pattern Glu/Lys10 (i) – Leu/Cys11 (iq1) –
Gly12 (iq2) – Lys/Glu13 (iq3) extracted from the sequence
alignment suggests that a loop-like structure could be
stabilized by a salt bridge/H-bond interaction of the pairs
of amino acids with oppositely charged side chains in
position i and iq3. To test this hypothesis, the side chains
of Glu10 and Lys13 within CP1B-w4y23x (7) were cova-
lently linked by macrolactamization. Furthermore, using
different combinations of acidic and basic amino acid
residues in positions i and iq3, the conformational free-
dom was restricted successively via the side chain
functions of these residues in a systematical manner.
Thereby, the sequence is forced into a restricted confor-
mation at this position, starting from a loose loop-like
structure and ending up in a tight turn. The sequences
of the four constrained peptides are shown in Figure 1B.
The synthesis of these conformationally constrained var-
iants of CP1B-w4–23x (7) is outlined in Figure 3. The pep-
tides were synthesized on solid support by the standard
Fmoc/tBu scheme. The basic residues in position iq3
were incorporated into the peptide chain Aloc-protected
and the acidic residues in position i Al-protected. Prior
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Figure 2 Amino acid sequence alignment of subdomains 1B,
2B, 3B and 4B of calpastatin from different mammalian species.
Positions of shown residues within the complete sequence are
given in parentheses. The amino acid residues reflecting the
consensus sequence pattern of the turn-like region (residues
10–13 which are supposed to constitute the turn as well as the
preceding residue 9 and the following residue 14) are highlighted
(residues i-1/iq4: black; residues i/iq3: dark-gray; residues iq1/
iq2: light-gray).
Figure 3 Synthesis of the conformationally constrained cal-
pastatin peptides.
Reaction conditions: (i) a. piperidine/NMP (1:5, v/v), b. Fmoc-
Xaa-OH/HBTU/HOBt/DIEA (1:1:1:2, 10 equiv.), NMP, 10 cycles
of automated single coupling; (ii) a. piperidine/NMP (1:5, v/v),
b. Fmoc-Xaa-OH/HBTU/HOBt/DIEA (1:1:1:1, 4 equiv.), DMF,
4 cycles of manual double coupling; (iii) Pd(PPh3)4 (0.1 equiv.),
PhSiH3 (5 equiv.), DCM; (iv) PyBOP/HOBt/DIEA (1:1:2, 5 equiv.),
DMF; (v) a. piperidine/NMP (1:5, v/v), b. Fmoc-Xaa-OH/HBTU/
HOBt/DIEA (1:1:1:2, 10 equiv.), NMP, 6 cycles of automated
double coupling; (vi) a. piperidine/NMP (1:5, v/v), b. Ac2O/2,6-
lutidine/DMF (5:6:89, v/v/v); (vii) TFA/H2O/TIS (95:2.5:2.5,
v/v/v).
Figure 4 3D visualization of the conformationally constrained
region (i.e., Glu9-Glu10-Leu11-Gly12-Dab13-Arg14) of peptide 16.
In the model, the N-terminus of this peptide portion is acetylated
and the C-terminus amidated. The peptide is shown in stick rep-
resentation, the amino acid residues Glu10, Leu11 and Arg13 are
labeled, and the loop-like conformation of the peptide backbone
is indicated by a gray ribbon.
to finishing the complete peptide sequence, the allyl-
based side chain protection was cleaved by Pd(0), and
the lactam bridge was formed using PyBOP, following a
procedure by Teixido et al. (2003).
Inhibition of m-calpain by conformationally
constrained variants of CP1B-w4–23x (7)
A comparison of the Ki values of the linear core sequence
7 with its cyclic counterpart 14 clearly shows that macro-
lactamization via the side chains of Glu10 and Lys13 does
not affect the inhibitory profile (Ki of 0.026 mM vs.
0.036 mM, respectively). Furthermore, starting from the
amino acid pair Glu(i)/Lys(iq3) (14), over Glu(i)/Orn(iq3)
(15), and Glu(i)/Dab(iq3) (16), to Asp(i)/Dab(iq3) (17), the
size of the macrolactam ring decreases stepwise by one
CH2-group. The Ki values of these peptides are sum-
marized in Table 1. The peptides 14, 15 and 16 are as
potent and selective as the linear core sequence 7. How-
ever, the constraint introduced by the amino acid pair
Asp(i)/Dab(iq3) with the smallest macrolactam ring is
accompanied by a substantial loss in affinity in compar-
ison to 7 (Ki of 1.4 mM vs. 0.026 mM, respectively).
3D visualization of the conformationally constrained
region
A 3D model of the conformationally constrained part of
16 induced by the macrolactam ring was built (Figure 4).
Besides the modified consensus sequence portion
(i)-(iq3), (Glu10-Leu11-Gly12-Dab13), the observation was
taken into account that within the subdomains 1, 3 and
4 the positions (i-1) preceding and (iq4) following this
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region are occupied in a systematical manner by an acid-
ic and a basic amino acid residue, respectively (see
above). Therefore, the residues i-1 (Glu9) and iq4 (Arg14)
were also included in the model. Inspection of the model
revealed a spatial array of a positively charged, a hydro-
phobic, and a negatively charged residue presented by
the loop region.
Discussion
To reduce the synthetic effort for SAR investigations with
the full-length calpastatin peptide, CP1B-w1–27x (1), we
were interested in a core sequence that reliably repro-
duces the affinity/selectivity profile of 1. Extending earlier
rough determinations of the affinity of truncated calpas-
tatin peptides (Uemori et al., 1990), the group of Anagli
has investigated the influence of truncation on the affinity
of 1 (Betts and Anagli, 2004). Including the aspect of
selectivity, we have reexamined these experiments,
using, besides cathepsin B, in particular cathepsin L as
a reliable marker to estimate the selectivity of inhibition
within the family of papain-like cysteine proteases. Gen-
erally, our data are consistent with the affinities previously
reported (Betts and Anagli, 2004). N-terminal truncation
of the full-length sequence by three amino acids (3,
Kis0.0006 mM; ratio CL/m-calpain 15 830) as well as
C-terminal truncation by four residues (6, Kis0.0008 mM;
ratio CL/m-calpain 26 250) does not influence the inhi-
bition profile compared to 1 (Kis0.0002 mM; ratio CL/m-
calpain 30 000). A combination of both truncations
yielded a calpastatin peptide of 20 amino acids length,
i.e., CP1B-w4–23x (7), which still displayed a reasonable
inhibitory profile (Kis0.026 mM; ratio CL/m-calpain 1000).
However, beyond this level of truncation (compounds
8 and 9) a drastic loss of affinity and selectivity was
observed. Thus, 7 represent a core sequence comprising
the minimum requirements to selectively block the pro-
teolytic activity of m-calpain among other papain-like
cysteine proteases.
NMR investigations of 1 in DMSO (Ishima et al., 1991)
suggest that the sequence portions Glu10-Leu11-Gly12-
Lys13 and Pro20-Lys21-Tyr22-Arg23 adopt turn-like confor-
mations. Furthermore, by a systematical b-Ala scan the
residues Leu11 and Gly12, as well as the residues Thr17,
Ile18, and Pro19, have been identified to be crucial for the
affinity of 1 (Betts et al., 2003). Together, these obser-
vations point towards two hot spots (Betts and Anagli,
2004) responsible for binding of 1 to calpain. Surprisingly,
peptides 10 and 11 comprising the individual first and
second hot spot region, respectively, exhibit only poor
inhibitory activities. Even an equimolar mixture of those
peptides did not reconstitute the inhibitory activity of 1
(Betts and Anagli, 2004). Based on these data, Anagli’s
group introduced the ‘gate model’ for the inhibition of
calpain: the peptide sequence between the two hot
spots, i.e., Lys13-Arg14-Glu15-Val16, positioned appropri-
ately by the interactions of the two hot spots with cal-
pain, act as a gate blocking the access of substrates to
the active site (Betts and Anagli, 2004). To gain more
information on the role of this gate, we have designed
peptide 12, based on the core sequence 7, where the
amino acid residues Arg14-Glu15-Val16 are replaced by the
flexible PEG amino acid 8-amino-3,6-dioxaoctanoic acid
that should provide a correct spatial arrangement of the
two hot spot regions. However, the low affinity of 12
(Kis11.7 mM) supports the notion that not only the cor-
rect spacing of the crucial binding elements is required
to restore the affinity of 1, but also the correct confor-
mation provided by the tripeptide sequence. Further-
more, the retro-inverso peptide of the core sequence (i.e.,
13, Kis726 mM) demonstrates that besides the correct
spatial positioning of the amino acid side chains, the
peptide back bone also has a strong influence on the
affinity.
The fact that the crucial amino acid residues Leu11 and
Gly12 (Betts et al., 2003) occupy the positions iq1 and
iq2 of the proposed b-turn (Ishima et al., 1991), respect-
ively, prompted us to analyze the amino acid sequence
of this region systematically. The sequence alignment of
peptides derived from subdomains 1B, 3B and 4B of dif-
ferent species revealed a consensus sequence for this
turn region, i.e., Glu/Asp9 (i-1)yGlu/Lys10 (i) – Leu11 (iq1)
– Gly12 (iq2) – Lys/Glu13 (iq3)yArg/Lys14 (iq4). However,
peptides derived from subdomains 2B show a substan-
tially different sequence pattern. Correspondingly, a com-
parison of the inhibitory potency of the subdomains 1B,
2B, 3B and 4B from rabbit calpastatin has revealed that
2B is by far the least potent inhibitor of m-calpain (Kawa-
saki et al., 1989). Very recently, these findings have been
confirmed by surface plasmon resonance measurements
(Hanna et al., 2007). It is striking to observe that in the
case of 1B peptides the residues Leu11 and Gly12 are
flanked by Glu in position i and Lys in position iq3,
whereas in the case of 3B and 4B peptides the basic Lys
(position i) is followed by an acidic Glu (position iq3). This
points towards a turn conformation at this site that
is possibly stabilized by a salt bridge interaction of the
oppositely charged side chain functionalities. Further-
more, one would expect that this type of local confor-
mation would orientate the oppositely charged residues
in position i-1 and iq4 in a defined spatial manner. To
test this hypothesis, 14 was synthesized where the puta-
tive salt bridge stabilized turn-like conformation in the
parent linear core sequence 7 was covalently fixed by
macrolactamization. A comparison of the Ki values clear-
ly shows that 14 is virtually as potent as 7 (Ki of 0.036 mM
vs. 0.026 mM). This finding is supportive for a turn-like
conformation stabilized by a salt bridge formed between
side chain carboxyl function of Glu10 and the side chain
amino function of Lys13.
To gain more information about the geometry of this
turn-like structure, the local conformational degrees of
freedom were successively reduced by stepwise removal
of CH2-groups within the macrolactam ring. The con-
straint induced by removal of one CH2-group (15) as well
as two CH2-groups (16) does not influence the inhibitory
profile substantially compared to 7 (Ki of 0.039 mM and
0.027 mM vs. 0.026 mM, respectively). However, removal
of three CH2-groups (17), corresponding conformationally
to a tight b-turn is accompanied with a severe loss of
inhibitory potency (Kis1.4 mM). These data clearly sup-
port the notion that the peptide portion Glu10-Leu11-Gly12-
Lys13 adopts a more loop-like structure rather than a
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b-turn as earlier proposed (Ishima et al., 1991), pointing
to a chain reversal of the 1B peptide at this site in the
peptide sequence. Moreover, it seems that in contrast to
the constrained variants 14, 15 and 16, in peptide 17 the
amino acid portion CP1B-w4–9x preceding the turn region
as well as the amino acid portion CP1B-w14–23x follow-
ing the turn region cannot adopt the proper orientation
and/or conformation upon binding to m-calpain.
Based on X-ray data of the interaction of a subdomain
1C peptide with domain VI of calpain and the homology
model of the interaction of a subdomain 1A peptide with
domain IV of calpain, models for the interaction of an
entire inhibitory domain of calpastatin with calpain have
been proposed (Todd et al., 2003; Wendt et al., 2004). To
properly connect the subdomains 1A and 1C, both mod-
els claim a reversal of the peptide chain within the region
corresponding to subdomain 1B. Our data derived from
the conformationally constrained variants of 7 presum-
ably indicate that the chain reversal is centered at the
tetrapeptide portion Glu10-Leu11-Gly12-Lys13.
The consensus sequence of the loop site revealed that
the polarity pattern of the residues i-1 (Glu or Asp: acidic)
preceding and iq4 (Lys, Arg: basic) following this loop is
highly conserved (Figure 2). The consequence of the
loop-like structure is that these particular residues occu-
py spatially defined positions. In combination with the
hydrophobic side chain of Leu11, which has been shown
to be highly sensitive to modifications (Betts and Anagli,
2004), these residues could be responsible for the cor-
rect positioning of the 1B peptide on the calpain surface
by addressing complementary binding pockets, and
thereby blocking the access of substrates to the active
site.
In conclusion, based on conformationally restricted
variants of subdomain 1B of human calpastatin, a first
model of the biologically active conformation has been
provided. In particular, macrolactamization studies
revealed that the tetrapeptide portion Glu10-Leu11-Gly12-
Lys13 adopts a loop-like conformation inducing a reversal
of the peptide chain at this site upon binding to
m-calpain.
Materials and methods
Materials
Solvents and reagents were of the highest purity commercially
available and were used without further purification. Amino acid
derivatives were purchased from Iris Biotech GmbH (Marktred-
witz, Germany) and Fluka (Buchs, Switzerland), the Rink-Amide
resin from NovaBiochem/Merck Biosciences AG (La¨ufelfingen,
Germany), Fmoc-8-amino-3,6-dioxaoctanoic acid fromNeoMPS
SA (Strasbourg, France), CP1B-w1–27x (1) as well as its scram-
bled derivative 2 from Calbiochem (Bad Soden, Germany). Auto-
mated peptide synthesis was carried out on a batch synthesizer
433A (Applied Biosystems, Foster City, CA, USA) equipped with
a UV/vis detector PE series 200 from Perkin Elmer (U¨berlingen,
Germany) for monitoring of the Fmoc-cleavage. Manual peptide
synthesis as well as all other manually performed synthetic steps
were carried out on an IKA KS 130 basic laboratory shaker (IKA
Werke GmbH, Staufen, Germany) using plastic syringes type
Discardit II from Becton Dickinson (Franklin Lakes, NJ, USA)
equipped with PE frits (35 mm pores size) and PE stoppers from
Roland Vetter Laborbedarf (Ammerbuch, Germany). LC-MS
mass spectra were recorded with a PE Sciex API 165 ESI-MS
spectrometer and a microgradient system 140 C (Applied Bio-
systems, Framingham, MA, USA). Nucleosil 100-5 C8 RP col-
umns (Macherey-Nagel, Du¨ren, Germany) were used with a
linear gradient of 0.1% TFA in H2O and 0.08% TFA in CH3CN
from 95:5 to 5:95. The MS spectra were processed with PE
Sciex BioMultiView software (V. 1.3.1, Applied Biosystems). Ana-
lytical RP-HPLC was performed with Waters equipments using
Chromolith Performance RP-18e (100=4.6 mm; VWR Interna-
tional GmbH, Darmstadt, Germany) columns and eluting with
linear gradients from 5% CH3CN in H2O/95% H3PO4 (2% in H2O)
to 90% CH3CN in H2O/10% H3PO4 (2% in H2O) within 6 min at
a flow rate of 3 ml/min. For preparative reversed-phase HPLC,
Gilson-Abimed equipments (Middleton, WI, USA) and Nucleosil
100-5 C18 columns (Macherey-Nagel) were used and com-
pounds were eluted with linear gradients of 0.1% TFA in H2O
and 0.08% TFA in CH3CN. The 3D model of the conformationally
constrained region of 16 was built using the program Hyper-
Chem (Release 3, Hypercube, Inc., Gainesville, FL, USA).
Synthesis of linear calpastatin peptides
The linear peptides were synthesized using an automated
peptide synthesizer according to the Fmoc/tBu strategy. Fmoc-
protected amino acid with the following side-chain protecting
groups were used: OtBu (Asp and Glu), tBu (Ser, Thr and Tyr),
Boc (Lys) and Pbf (Arg). In the case of the retro-inverso peptide
13, the corresponding D-amino acids were used. The coupling
was performed with Fmoc-Xaa-OH/HBTU/HOBt/DIEA (1:1:1:2,
10 equiv.) in NMP using the standard FastMoc protocol
(Applied Biosystems) for single and double coupling, respective-
ly. Unless otherwise stated, single coupling was performed. The
loading of the Rink-Amid resin (0.1 mmol) with the first amino
acid was also performed using the synthesizer under the same
conditions as for a single coupling step. After each coupling
step, the Fmoc group was cleaved using piperidine/NMP
(1:5, v/v). The acetylation of the N-terminal amino group was
performed manually using Ac2O/2,6-lutidine/DMF (5:6:89, v/v/v).
The final deprotection was also carried out manually using TFA/
H2O/TIS (95:2.5:2.5, v/v/v). The crude peptides were precipitated
by adding the cleavage solution dropwise into ice-cold tert-butyl
methyl ether/hexane (2:1, v/v). The precipitate was collected
by centrifugation and purified by preparative RP-HPLC. Homog-
enous fractions were pooled and lyophilized.
Ac-SSTYIEELGKREVTIPPKYRELLA-NH2 (3) Double coup-
ling starting with the 4th Glu; colorless lyophilisate: yield: 164
mg (58%); HPLC (tRs2.1 min); ESI-MS: m/zs1418.0 wMq2Hx2q,
945.8 wMq3Hx3q, 709.4 wMq4Hx4q; Mrs2834.29 calculated for
C128H209N33O39.
Ac-TYIEELGKREVTIPPKYRELLA-NH2 (4) Double coupling
starting with the 4th Glu; colorless lyophilisate: yield: 183 mg
(69%); HPLC (tRs2.1 min); ESI-MS: m/zs1330.8 wMq2Hx2q,
887.4 wMq3Hx3q, 666.0 wMq4Hx4q; Mrs2660.13 calculated for
C122H199N31O35.
Ac-DPMSSTYIEELGKREVTIPPKYREL-NH2 (5) Double cou-
pling starting with the 4th Glu; colorless lyophilisate: yield: 197
mg (66%); HPLC (tRs2.0 min); ESI-MS: m/zs1498.0 wMq2Hx2q,
998.4 wMq3Hx3q, 748.8 wMq4Hx4q; Mrs2993.39 calculated for
C133H214N34O42S.
Ac-DPMSSTYIEELGKREVTIPPKYR-NH2 (6) Double coup-
ling starting with the 3rd Glu; colorless lyophilisate: yield: 195
mg (71%); HPLC (tRs1.9 min); ESI-MS: m/zs1376.4 wMq2Hx2q,
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918.0 wMq3Hx3q, 688.6 wMq4Hx4q; Mrs2751.18 calculated for
C122H196N32O38S.
Ac-SSTYIEELGKREVTIPPKYR-NH2 (7) Double coupling
starting with the 3rd Glu; colorless lyophilisate: yield: 180 mg
(75%); HPLC (tRs1.8 min); ESI-MS: m/zs1204.8 wMq2Hx2q,
803.4 wMq3Hx3q, 603.0 wMq4Hx4q; Mrs2407.77 calculated for
C108H175N29O33.
Ac-TYIEELGKREVTIPPKYR-NH2 (8) Double coupling start-
ing with the 3rd Glu; colorless lyophilisate: yield: 148 mg (66%);
HPLC (tRs1.8 min); ESI-MS: m/zs1117.6 wMq2Hx2q, 745.4
wMq3Hx3q, 559.4 wMq4Hx4q; Mrs2233.62 calculated for
C102H165N27O29.
Ac-SSTYIEELGKREVTIPPK-NH2 (9) Double coupling start-
ing with the 3rd Glu; colorless lyophilisate: yield: 153 mg (73%);
HPLC (tRs1.8 min); ESI-MS: m/zs1044.8 wMq2Hx2q, 697.0
wMq3Hx3q; Mrs2088.41 calculated for C93H154N24O30.
Ac-DPMSSTYIEELGK-NH2 (10) Colorless lyophilisate: yield:
109 mg (72%); HPLC (tRs2.0 min); ESI-MS: m/zs1511.8
wMqHxq, 756.2 wMq2Hx2q; Mrs1510.7 calculated for
C65H103N15O24S.
Ac-REVTIPPKYRELLA-NH2 (11) Colorless lyophilisate:
yield: 134 mg (78%); HPLC (tRs1.8 min); ESI-MS: m/zs1727.4
wMqHxq, 864.0 wMq2Hx2q, 576.2 wMq3Hx3q; Mrs1726.1 calcu-
lated for C79H132N22O21.
Ac-SSTYIEELGK-NH-(CH2O)2-CH2C(O)-TIPPKYR-NH2 (12)
Double coupling starting with the 2nd Glu; colorless lyophilisate:
yield: 95 mg (44%); HPLC (tRs1.8 min); ESI-MS: m/zs1084.8
wMq2Hx2q, 723.8 wMq3Hx3q; Mrs2168.45 calculated for
C98H158N24O31.
Ac-rykppitverkgleeiytss-NH2 (13) Double coupling starting
with Val; colorless lyophilisate: yield: 98 mg (41%); HPLC (tRs2.3
min); ESI-MS: m/zs1205.0 wMq2Hx2q, 803.6 wMq3Hx3q, 603.0
wMq4Hx4q; Mrs2407.8 calculated for C108H175N29O33.
Synthesis of conformationally constrained
calpastatin peptides
The peptide sequence REVTIPPKYR was synthesized using a
Rink-Amide resin (0.1 mmol), as described for the linear pep-
tides. The following four amino acids corresponding to the
sequence X2LGX1 (14: X1sLys, X2sGlu; 15: X1sOrn, X2sGlu; 16:
X1sDab, X2sGlu; 17: X1sDab, X2sAsp) were added manually by
double coupling (60 min for each coupling step) with Fmoc-Xaa-
OH/HBTU/HOBt/DIEA (1:1:1:1, 4 equiv.) in DMF (3 ml). The side
chains of Asp and Glu were OAl, those of Lys, Orn and Dab
Aloc-protected. After each coupling step, the resin was washed
with DMF, DCM and iPrOH sequentially (3=3 ml each). To cleave
the allyl-based protecting groups, the N-terminally Fmoc-pro-
tected resin-bound peptide was treated (3=15 min) with
Pd(PPh3)4 (0.1 equiv.) and PhSiH3 (5 equiv.) in dry DCM (3 ml)
under an argon atmosphere. Upon each treatment, the resin was
washed with dry DCM (2=3 ml). Finally, the resin was washed
with DMF, DCM and iPrOH sequentially (3=3 ml each). The
macrolactamization (2=120 min coupling time) was carried out
with PyBOP/HOBt/DIEA (1:1:2, 5 equiv.). In the particular case
of 17 (X1sDab, X2sGlu), it was necessary to repeat the macro-
lactamization step a third time overnight to complete the reac-
tion. The remaining sequence was built up using the synthesizer
(double coupling, 10 equiv.). N-terminal acetylation, final depro-
tection and purification was performed as described for the lin-
ear peptides.
14 Colorless lyophilisate: yield: 115 mg (48%); HPLC (tRs2.0
min); ESI-MS: m/zs1195.6 wMq2Hx2q; 797.6 wMq3Hx3q;
Mrs2389.75 calculated for C108H173N29O32.
15 Colorless lyophilisate: yield: 99 mg (42%); HPLC (tRs2.6
min); ESI-MS: m/zs1188.4 wMq2Hx2q; 792.8 wMq3Hx3q;
Mrs2375.74 calculated for C107H171N29O32.
16 Colorless lyophilisate: yield: 116 mg (49%); HPLC (tRs2.3
min); ESI-MS: m/zs1181.8 wMq2Hx2q; 788.4 wMq3Hx3q;
Mrs2361.73 calculated for C106H169N29O32.
17 Colorless lyophilisate: yield: 65 mg (28%); HPLC (tRs1.7
min); ESI-MS: m/zs1175.2 wMq2Hx2q; 784.0 wMq3Hx3q;
Mrs2347.67 calculated for C105H167N29O32.
Inhibition assays and Ki determination
Enzymes and substrates were obtained as outlined in Gil-
Parrado et al. (2003). Inhibition of m-calpain (0.5–1 nM) was
measured at 128C (to slow down inactivation by autolysis) with
the fluorogenic substrate Suc-LY-amc (400 mM) in 50 mM Tris/
HCl, pH 7.5, 100 mM NaCl, 0.015% Brij-35, (calpain buffer) and
150–200 mM CaCl2, 1 mM dithiothreitol (DTT). Cathepsin L (5 pM)
was assayed at 258C with Z-FR-amc (4 mM) and cathepsin B
(25 pM) at 308C with Z-FR-amc (10 mM) in 0.25 M sodium acte-
tate, pH 5.5, 2 mM EDTA, 0.015% Brij-35, 1 mM dithiothreitol,
freshly added. Continuous assays were performed recording flu-
orescence (excitation 380 nm, emission 460 nm) essentially as
described in Machleidt et al. (1993). The enzymes were preac-
tivated with DTT in the presence of substrate and CaCl2 (only
with m-calpain). Then approximately 5–10 different inhibitor con-
centrations were added in maximal 1% of the total test volume
of 500 ml (dissolved and prediluted in calpain buffer) and the
reaction was followed until equilibrium was reached. Ki values
for the inhibition of m-calpain were obtained from presteady
state kinetics, fitting the progress data by non-linear regression
analysis to the integrated equation of Morrison (1982). From the
rate constants kon and koff, the Ki values were calculated as
Kiskoff/kon. For cathepsin L and B, the inhibition constants were
calculated from the initial and steady state rates using the equa-
tion of classical inhibition. Ki values were corrected for compe-
tition with the substrates. In cases of less than 10% inhibition,
the Ki value was assumed to be at least 10-fold the highest used
inhibitor concentration.
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